A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for Suspension
Status:
Completed
Trial end date:
2023-09-04
Target enrollment:
Participant gender:
Summary
This study is divided into three parts: bioavailability study (hereinafter referred to as "BA
study"), food effect study (hereinafter referred to as "FE study") and pharmacokinetic
characteristics study (hereinafter referred to as "PK characteristics study"). A total of 38
subjects are planned to be enrolled. The three parts of the study can be carried out
simultaneously, and there is no order requirement. The subjects will be assigned to one of
them according to the enrollment order. Dose selection is 100mg, 300mg and 25mg.